Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.

BVXV

BiondVax Pharmaceuticals (BVXV)

BiondVax Pharmaceuticals Ltd
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:BVXV
DateTimeSourceHeadlineSymbolCompany
04/30/20243:06PMEdgar (US Regulatory)Form NT 20-F - Notification of inability to timely file Form 20-FNASDAQ:BVXVBiondVax Pharmaceuticals Ltd
04/16/20244:27PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:BVXVBiondVax Pharmaceuticals Ltd
04/10/20246:00AMPR Newswire (US)Scinai to showcase its novel biological local therapeutic for Plaque Psoriasis at Dermatology Drug Development Summit together with Prof. Michael Schön of UMGNASDAQ:BVXVBiondVax Pharmaceuticals Ltd
03/12/20243:17PMEdgar (US Regulatory)Form SC 13D - General statement of acquisition of beneficial ownershipNASDAQ:BVXVBiondVax Pharmaceuticals Ltd
03/12/20247:00AMPR Newswire (US)Scinai leadership to attend BIO-Europe Spring 2024NASDAQ:BVXVBiondVax Pharmaceuticals Ltd
02/13/20246:00AMPR Newswire (US)Scinai Welcomes Liat Halpert as Head of Business Development and SalesNASDAQ:BVXVBiondVax Pharmaceuticals Ltd
01/04/20243:01PMPR Newswire (US)Scinai Immunotherapeutics Announces Closing of Exercise of Outstanding Warrants for $1.69 Million in Gross ProceedsNASDAQ:BVXVBiondVax Pharmaceuticals Ltd
11/20/20236:30AMPR Newswire (US)Scinai Immunotherapeutics Regains Compliance with Nasdaq's Stockholders' Equity RuleNASDAQ:BVXVBiondVax Pharmaceuticals Ltd
09/07/20234:27PMEdgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:BVXVBiondVax Pharmaceuticals Ltd
09/06/202311:01AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:BVXVBiondVax Pharmaceuticals Ltd
09/06/202310:44AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:BVXVBiondVax Pharmaceuticals Ltd
09/06/20235:00AMGlobeNewswire Inc.BiondVax Pharmaceuticals Ltd. Rebrands as Scinai Immunotherapeutics Ltd. to Reflect New Focus on Development of Novel Inflammation and Immunology (I&I) Biological TherapeuticsNASDAQ:BVXVBiondVax Pharmaceuticals Ltd
08/28/20233:01PMEdgar (US Regulatory)Form 424B2 - Prospectus [Rule 424(b)(2)]NASDAQ:BVXVBiondVax Pharmaceuticals Ltd
08/27/202311:15PMEdgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:BVXVBiondVax Pharmaceuticals Ltd
08/24/20233:05PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:BVXVBiondVax Pharmaceuticals Ltd
08/23/20235:10AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:BVXVBiondVax Pharmaceuticals Ltd
08/18/20233:16PMEdgar (US Regulatory)Form F-3 - Registration statement by foreign private issuersNASDAQ:BVXVBiondVax Pharmaceuticals Ltd
08/18/20239:07AMEdgar (US Regulatory)Form 6-K/A - Report of foreign issuer [Rules 13a-16 and 15d-16]: [Amend]NASDAQ:BVXVBiondVax Pharmaceuticals Ltd
08/14/20235:08AMEdgar (US Regulatory)Form 6-K/A - Report of foreign issuer [Rules 13a-16 and 15d-16]: [Amend]NASDAQ:BVXVBiondVax Pharmaceuticals Ltd
08/11/20238:44AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:BVXVBiondVax Pharmaceuticals Ltd
08/11/20238:00AMGlobeNewswire Inc.BiondVax Reports Second Quarter Financial Results and Provides Business UpdateNASDAQ:BVXVBiondVax Pharmaceuticals Ltd
08/01/20233:01PMGlobeNewswire Inc.Nasdaq Grants BiondVax Extension to Regain Compliance with Listing RulesNASDAQ:BVXVBiondVax Pharmaceuticals Ltd
08/01/20233:00PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:BVXVBiondVax Pharmaceuticals Ltd
07/12/20232:10PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:BVXVBiondVax Pharmaceuticals Ltd
07/11/20237:17AMGlobeNewswire Inc.IBN Announces Latest Episode of The Bell2Bell Podcast featuring Amir Reichman, CEO of BiondVax Pharmaceuticals Ltd.NASDAQ:BVXVBiondVax Pharmaceuticals Ltd
07/05/20238:17AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:BVXVBiondVax Pharmaceuticals Ltd
07/03/20233:10PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:BVXVBiondVax Pharmaceuticals Ltd
07/03/20233:05PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:BVXVBiondVax Pharmaceuticals Ltd
06/08/20233:31PMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:BVXVBiondVax Pharmaceuticals Ltd
06/05/20236:00AMGlobeNewswire Inc.BiondVax signs exclusive license agreement for development and commercialization of a novel anti-IL-17 antibody for treatment of autoimmune and inflammatory diseases including psoriasisNASDAQ:BVXVBiondVax Pharmaceuticals Ltd
 Showing the most relevant articles for your search:NASDAQ:BVXV